According to the Journal of Cardiac Failure, HFpEF represents more than half of all heart failure world-wide. In the United States, it accounts for over 3.5 million heart failure cases.

Valsartan, an angiotensin II receptor blocker drug, delayed disease progression and improved cardiac structure and function in patients with early-stage hypertrophic cardiomyopathy, according to ...